Lawrence D. Mayer

Lawrence D. Mayer's AcademicInfluence.com Rankings

Lawrence D. Mayer

Chemistry

#4808

World Rank

#5900

Historical Rank

Physical Chemistry

#761

World Rank

#816

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Lawrence D. Mayer's Degrees

PhD Chemistry University of California, Berkeley
Bachelors Chemistry University of California, Berkeley

Why Is Lawrence D. Mayer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence D. Mayer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Vesicles of variable sizes produced by a rapid extrusion procedure. (1986) (1572)
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. (2000) (1032)
Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. (1985) (433)
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. (1989) (373)
Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol) (2002) (360)
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. (1986) (354)
The liposomal formulation of doxorubicin. (2005) (345)
Generation of multilamellar and unilamellar phospholipid vesicles (1986) (341)
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice (2006) (289)
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. (2009) (287)
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. (2011) (276)
Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. (1990) (238)
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. (1990) (237)
Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. (1995) (232)
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. (2003) (228)
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. (1997) (206)
Optimizing combination chemotherapy by controlling drug ratios. (2007) (201)
A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form (2001) (195)
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. (2000) (191)
Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. (1985) (191)
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors (2009) (183)
Techniques for encapsulating bioactive agents into liposomes. (1986) (181)
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. (1998) (157)
Formation of transition metal-doxorubicin complexes inside liposomes. (2002) (144)
Liposomes with entrapped doxorubicin exhibit extended blood residence times. (1990) (128)
Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. (1994) (128)
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. (2007) (127)
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. (2010) (127)
Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. (1990) (124)
Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. (2001) (121)
Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. (2001) (119)
In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. (2000) (112)
Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. (2000) (111)
In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading (2004) (111)
Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel (1997) (109)
Phase I study of liposomal vincristine. (1999) (104)
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. (2008) (103)
The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. (1997) (101)
Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. (1990) (98)
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. (2004) (97)
Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. (2000) (95)
Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo (2009) (93)
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. (2012) (89)
Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. (2003) (88)
Effects of block copolymer properties on nanocarrier protection from in vivo clearance. (2012) (88)
Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. (1997) (87)
Generating and loading of liposomal systems for drug-delivery applications (1989) (87)
Disc formation in cholesterol-free liposomes during phase transition. (2003) (87)
Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. (2002) (84)
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. (1999) (84)
Optimization of the retention properties of vincristine in liposomal systems. (1993) (83)
Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. (2005) (81)
Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. (1995) (79)
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin (2004) (77)
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. (2006) (76)
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. (2011) (71)
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. (2004) (70)
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. (2002) (66)
Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia (2004) (65)
Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer (1998) (65)
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. (2002) (64)
Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo (2010) (64)
Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression (2000) (63)
Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. (1993) (63)
Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy (1995) (61)
Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug‐resistant solid tumors by co‐administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin (2000) (60)
Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). (2001) (60)
Preparation, characterization, and biological analysis of liposomal formulations of vincristine. (2005) (60)
Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. (1995) (57)
Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. (2010) (56)
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties (2019) (55)
Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. (1990) (55)
Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. (2001) (54)
Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes (2004) (54)
Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. (1988) (53)
Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transition. (2006) (53)
Improving combination cancer therapy: the CombiPlex® development platform. (2018) (53)
Kinetic and hydrodynamic analysis of blood clotting factor V-membrane binding. (1982) (52)
The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin (1994) (52)
Tumor chemosensitization strategies based on apoptosis manipulations. (2003) (50)
Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. (1993) (50)
Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs (1994) (46)
Molecular and pharmacological strategies to overcome multidrug resistance (2001) (46)
Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. (1989) (45)
The Role for Liposomal Drug Delivery in Molecular and Pharmacological Strategies to Overcome Multidrug Resistance (2004) (44)
P‐glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells (2004) (44)
Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. (1985) (44)
Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. (2014) (44)
-REDUCTION OF LIPOSOME SIZE AND PREPARATION OF UNILAMELLAR VESICLES BY EXTRUSION TECHNIQUES (2002) (43)
Calcium and prothrombin-induced lateral phase separation in membranes. (1981) (42)
Prothrombin association with phospholipid monolayers. (1983) (42)
Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. (2009) (40)
The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. (1995) (40)
Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations (1998) (40)
Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. (1993) (40)
Influence of ion gradients on the transbilayer distribution of dibucaine in large unilamellar vesicles. (1988) (39)
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. (2002) (37)
Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts (2001) (37)
High ceramide content liposomes with in vivo antitumor activity. (2003) (36)
Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. (2007) (36)
Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection (1998) (36)
pH gradients and membrane transport in liposomal systems. (1991) (35)
Strategies for Optimizing Liposomal Doxorubicin (1990) (35)
Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. (1999) (35)
Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. (2001) (34)
Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. (1999) (33)
Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. (1997) (33)
Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model (2004) (32)
Influence of vesicle size on complement-dependent immune damage to liposomes. (1986) (32)
Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. (2002) (31)
Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice (2004) (31)
Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts (2010) (31)
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. (2007) (31)
Phosphatidic acid as a calcium ionophore in large unilamellar vesicle systems. (1984) (30)
Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. (2003) (30)
The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). (1999) (29)
Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. (2010) (27)
Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer (2004) (27)
Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications (2000) (26)
Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations (2011) (26)
Liposomal Irinotecan: Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer (2004) (25)
Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: correlation with Western blot analysis. (2000) (25)
Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations (1998) (25)
449 PH GRADIENT LOADING OF ANTHRACYCLINES INTO CHOLESTEROL-FREE LIPOSOMES: ENHANCING DRUG LOADING RATES THROUGH USE OF ETHANOL. (2004) (25)
Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. (2003) (24)
Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. (2003) (23)
Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes (2016) (22)
Drug interaction studies between paclitaxel (Taxol) and OC144-093 — A new modulator of MDR in cancer chemotherapy (2002) (22)
CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. (2017) (22)
CHAPTER 4.2 – Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes (1998) (20)
Association of Blood Coagulation Factors V and X with Phospholipid Monolayers (1983) (18)
Intra and Inter-Molecular Interactions Dictate the Aggregation State of Irinotecan Co-Encapsulated with Floxuridine Inside Liposomes (2008) (18)
Characterization of cholesterol hemisuccinate and α-tocopherol hemisucccinate vesicles (1988) (18)
Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies (1998) (17)
Efficacy of CPX‐351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program (2015) (17)
Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer (2001) (16)
Membrane lateral phase separation induced by proteins of the prothrombinase complex (1983) (16)
Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. (1997) (13)
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. (2013) (11)
Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. (2020) (11)
CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia (2015) (10)
Liposomal Anticancer Drugs as Agents to be used in Combination with other Anticancer Agents: Studies on a Liposomal Formulation with two Encapsulated Drugs (1999) (10)
Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias (2008) (10)
Drug-Drug Interactions Arising From the Use of Liposomal Vincristine in Combination with Other Anticancer Drugs (2001) (9)
Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS). (2007) (9)
Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors. (2006) (9)
Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation (2016) (9)
Visualization of bioavailable liposomal doxorubicin using a non-perturbing confocal imaging technique. (2001) (7)
Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes (2001) (7)
Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors. (2003) (7)
Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. (1995) (6)
Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells (2004) (6)
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias (2019) (6)
pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice (2005) (6)
The Development of Liposomes for Enhanced Delivery of Chemotherapeutics to Tumors (2002) (6)
Clinical and Preclinical Pharmacology of Liposomal Vincristine (2000) (6)
Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications (2008) (5)
Abstract 5464: Determination of total and encapsulated drug pharmacokinetics for CPX-351, a nanoscale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun) (2011) (5)
Detection of protein-free lipoprotein analogues with an apolar lipid core by freeze-etch electron microscopy. (1987) (4)
Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection. (2009) (4)
Liposomes for Cancer Therapy Applications (2001) (4)
Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy (2007) (4)
Applications of Liposome Technology to Overcome Multidrug Resistance in Solid Tumors (1998) (3)
Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD (2017) (3)
Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells (2010) (3)
Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein. (2002) (3)
Characterization of cholesterol hemisuccinate and alpha-tocopherol hemisuccinate vesicles. (1988) (2)
Synergistic Cytarabine:Daunorubicin Ratios Delivered by CPX-351 to Human Leukemia Xenografts Is Associated with Liposome-Mediated Bone Marrow Drug Accumulation, Intracellular Delivery of Encapsulated Agents to Leukemia Cells, and Increased Efficacy. (2008) (2)
Paclitaxel conjugate block copolymer nanoparticle formation by flash NanoPrecipitation (2006) (2)
A pharmaceutical approach to achieve synergy in vivo: A fixed ratio formulation of Irinotecan and Floxuridine for treatment of colorectal cancer (2004) (2)
The Use of Radioactive Marker as a Tool to Evaluate the Drug Release in Plasma and Particle Biodistribution of Block Copolymer Nanoparticles (2011) (2)
Abstract 1292: Pharmacokinetics of CPX-351: A nano-scale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun) in patients with advanced leukemia (2011) (2)
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML. (2018) (2)
Quantitative Whole Body Autoradiography (QWBA) Analysis Reveals That CPX-351 Shifts the Exposure of Cytarabine (Cyt) and Daunorubicin (Daun) Away from Many Tissues While Providing Prolonged Exposure to Cytotoxic Drug Concentrations in the Bone Marrow Compared to Conventional Free Drug Administration (2014) (1)
A novel approach to prepare a liposomal irinotecan formulations that exhibit significant therapeutic activity in vivo (2004) (1)
Abstract 2526: Detection of Ara-CTP following exposure to CPX-351 and potentiation of action by fludarabine in leukemia cell lines using a bioluminescent bacterial biosensor (2015) (1)
Liposome formulations with high antineoplastic drug / lipid ratio (1988) (1)
Versatile Fixed-Ratio Drug Combination Delivery Using Hydrophobic Prodrug Nanoparticles (2012) (1)
In‐vitro Evaluation of Doxorubicin Cytotoxicity and Cellular Uptake in the Presence and Absence of Multidrug Resistance Modulators (1999) (1)
Oral Presentations—Abstracts (2003) (1)
Abstract 287: CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes (2016) (1)
O-288 Anti-metastatic and anti-tumor efficacy of G3139, a Bcl-2 antisense oligonucleotide, as single agent or in combination with vinorelbine, in murine orthotopic and ectopic xenograft models of human non-small cell lung cancer (2003) (1)
Abstract 3698: Development of a hydrophobic docetaxel prodrug nanoparticle with enhanced plasma circulation lifetime and improved efficacy (2010) (1)
Abstract 3479: CPX-351 (cytarabine:daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition (2015) (1)
Preparation antibiotique a base de liposomes (1987) (0)
Nano-scale Carriers to Coordinate the In Vivo Delivery of Anticancer Drug Combinations (2013) (0)
Reduction of rate of releasing medicine from liposome (1994) (0)
Anhydrovinblastine to treat cancer (1998) (0)
Formulations of liposomal antineoplastic agents with high drug-lipid ratio (1989) (0)
CPX-351 Markedly Reduces Renal and Hepatic Clearance Rates for Cytarabine (Cyt) and Daunorubicin (Daun) in Rats with an Associated Decrease in Excretory and Metabolic Burden Despite Providing Dramatic Increases in Systemic Drug Exposure Compared to Conventional Cyt+Daun (2014) (0)
Patent Number : 5 , 795 , 589 45 ) Date of Patent : * Aug . 18 , 1998 (2017) (0)
Dehydrated liposome pharmaceutical preparation (1994) (0)
PHOSPHATIDIC ACID AS A CALCIUM I O N O P H O R E IN LARGE VESICLE SYSTEMS (2002) (0)
Compositions d'excipient a base de lipides ayant des fonctions de reaction au moyen d'une surface protegee (2000) (0)
Liposomes containing Guanidinaminoglycosid (1987) (0)
[Recent advances in the treatment of cancer]. (1950) (0)
Liposome formulations with high antineoplastic / lipid agent relationship. (1988) (0)
LUV with saturated phospholipids and methods for their preparation (1988) (0)
Renal impairment impact on CPX-351 pharmacokinetics and safety. (2015) (0)
Abstract A135: Evaluation of CPX‐351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models (2009) (0)
Loading of medicine into liposome (1994) (0)
Solid drug ratio for the treatment of hematopoietic cancers and proliferative disorders (2008) (0)
World Increase of Cancer. (0)
Transport lipids compositions with improved blood stability (2002) (0)
Compositions d'excipient a base de lipides pour retention medicamenteuse amelioree (2001) (0)
Abstract B34: Coordinated delivery of anticancer drug combinations incorporating molecularly targeted agents provides markedly increased plasma drug exposure, decreased toxicity and increased efficacy in preclinical tumor models (2015) (0)
Combinations of water-soluble camptothecin liposomal cetuximab or bevacizumab (2009) (0)
Proton flux inlarge unilamellar vesicles inresponse tomembrane potentials andpHgradients (1989) (0)
Anhydrovinblastine for treating cancer (1998) (0)
Leukemia Cell–Selective Uptake of Cytarabine and Daunorubicin in the Bone Marrow Compartment Mediated by CPX-351 Liposome Injection (2010) (0)
Vesicles comprising phospholipids large unilamellar saturated and method for its preparation. (1988) (0)
Abstract 5534: Liposome accumulation within leukemia engrafted bone marrow is significantly enhanced when the formulation contains cytarabine plus daunorubicin (2010) (0)
Sphingosomes for improved drug delivery. (1995) (0)
Reply to Madewell and Kraegel (1995) (0)
Pharmacological fixed relationships for treating hematopoietic cancers and proliferative disorders (2008) (0)
Anhydrovinblastine for treatment of cancer (1998) (0)
Uptake of ant ineoplast ic agents into large uni lamei lar vesicles in response to a membrane potent ia l (2002) (0)
Drug encapsulation in biodegradable polymer carriers using a confined tangential flow mixer (2005) (0)
Exploiting Drug Ratio – Dependent Informatics : Nano-Scale Delivery Vehicles In Vivo (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence D. Mayer?

Lawrence D. Mayer is affiliated with the following schools: